New hope for tough lung cancers: experimental drug combo tested

NCT ID NCT05020457

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specific type of lung cancer (EGFR and ALK negative) and have already tried immunotherapy and/or chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China
Shandong Cancer Hospital

Jinan, Shandong, China
Sun Yat-sen University Cancer Center (SYSUCC)

Guangzhou, Guangdong, 510075, China
TaiZhou Hospital of Zhejiang Province

Taizhou, Zhejiang, China
The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.